Navigation Links
Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
Date:11/11/2008

SAN DIEGO, Nov. 11 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced financial results for the third quarter and nine months ended September 30, 2008, and highlighted several recent product developments and corporate milestones.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

Recent product and corporate highlights:

o On October 8, 2008, the company announced that it will initiate a

corporate restructuring that will extend the company's financial

resources to pursue near-term corporate development opportunities,

including completion of a merger and acquisition (M&A) transaction,

the sale of specific programs, and/or completion of other

alternative financial arrangements.

o The company announced positive clinical results from its Phase 1

trial of HspE7, a therapeutic treatment for patients with cervical

intraepithelial neoplasia, or CIN, a precursor to cervical cancer.

During the third quarter, immunological data from the fourth and

final cohort of the Phase 1 trial demonstrated absolute levels of

HPV16 E7-specific T-cells in patients were similar to levels

observed in the third cohort. Patients in the fourth cohort were

administered 500 mcg of HspE7 and 2,000 mcg of Poly-ICLC. These data

support doses of 500 mcg of HspE7 and 1,000-2,000 mcg of Poly ICLC

as appropriate for advancing into Phase 2 studies.

o During the quarter, the company won a challenge to its European

patent covering the company's lead product candidate, HspE7, and

other human papillomavirus (HPV) therapeutics.

o Nventa presented positive data from preclinical studies using its

proprietary Toll-like Receptor 3 agonis
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
8. Nventa Appoints John Varian to Board of Directors
9. Nventa Appoints Gordon H. Busenbark to Board of Directors
10. Nventa Provides Corporate Update and Advancement Plans for HspE7, Hsp 6/11 and Poly-ICR
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)..., , COPENHAGEN, Dec. 2 Th... with BioIsoprene technology, a breakthrough alter...dient in the manufacture of synthetic rubber with ... Denmark, this week. One tire will be on display a...enhagen International Airport throughout December ...
(Date:12/2/2009)..., , LIBREVILLE, Gabon, December 2 /PR... in Africa: Everyone,s Problem and Heritage" ,,...odiversity, 2-3 June 2010 the,Gabonese Republic is...,(Gabon) on the issue of safeguarding biological r...d by government and state leaders, ministers,scie...
(Date:12/2/2009)..., , JERUSALEM, Israel, December...easibility study evaluating the preclinical (anima...duct which combines technology from Weill,Cornell ...ave potential to,treat inherited anemias such as C...ng a series of technologies to expand, ex vivo,po...
(Date:12/2/2009)..., , NANJING, China, Dec. 2 /PRNewsw...e" or the "Company") (NYSE: SCR ), a leading pha...t, manufacturing, and marketing of branded,generic...nnounced that 105 of,its drugs have been included ..."), which was issued by China,s Ministry of Human ...
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Libreville International Conference 2-3 June 2010 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
...ter With Patented Triple Arterial Lumen ... /PRNewswire-FirstCall/ - Angiotech Pharmaceutical...that it will introduce and,exhibit its innovative ...08,Society of Interventional Radiology (SIR) Annua...from March 15-18, 2008., "It,s exciting to partic...
...orporated,(Nasdaq: VPHM ) today announced that Vi...erating officer of ViroPharma, will present at the...e at 1:40 P.M. ET on Tuesday,March 18, 2008. The c...ley,Place., ViroPharma,s presentation will be web...arma.com and available through April 1, 2008., A...
...cs plc,(AIM: SLN) today announces a collaboration ...ment of a range of novel approaches for the delive...Therapeutics, leading,expertise in the delivery of...he functional systemic delivery of siRNA in vivo u...cial details of this,collaboration, in which both ...
Other Biology Technology:Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting 2Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting 3Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting 4Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting 5Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 2Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery 3
(Date:12/3/2009)...en and his co-workers discovered that specific typ...ncer. Scientists soon found out how these pathogen...t the main culprits are viral proteins E6 and E7. ...l functions, thus promoting cell growth. , Prof...e now discovered another mechanism by which the E6...
(Date:12/3/2009)...ar panels that repels grime and dirt? Expanded bat... New Tel Aviv University research, just published ... in assembling peptides at the nano-scale level th...n just a few years. , Operating in the range of ...and even smaller, graduate student Lihi Adler-Abra...
(Date:12/3/2009)...entists believe that staph infections are caused b...mit toxins. The signaling process is called quorum...start the process. , But the Jeff Brinker resear...of staph infection, when bacteria switch from a ha... and that this individual process can be stopped b...
Breaking Biology News(10 mins):Papillomavirus silences innate immune response 2A window that washes itself? 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3New Precision Radiation Treatment System Fights Cancer 55423 1New Precision Radiation Treatment System Fights Cancer 55423 2New Precision Radiation Treatment System Fights Cancer 55423 3Low Carb Diet Referenced in BIDMC Study Not Related to Atkins 55420 1Low Carb Diet Referenced in BIDMC Study Not Related to Atkins 55420 2Low Carb Diet Referenced in BIDMC Study Not Related to Atkins 55420 3Low Carb Diet Referenced in BIDMC Study Not Related to Atkins 55420 4Low Carb Diet Referenced in BIDMC Study Not Related to Atkins 55420 5The Omics Generation on Facebook 55415 1The Omics Generation on Facebook 55415 2
..., 2008) Two studies published in the current iss...ficacy of transplanting bone marrow cells (BMCs) f...ound that implanting adult cardiomyocytes (heart m...ntages over transplanting cardiomyocytes alone. Fi...nting cardiomyocytes alone, the therapeutic effect...
...d sleep medicine specialists from two Michigan uni... to put innovative quantitative analysis, signal-p...rk in the sleep lab. One of their recent findings...tation appears to distinguish fibromyalgia patient...search scientist and engineer at the Michigan Tech...
...ork, Departmental and Workgroup Scanners Recognize... Equipment SUNNYVALE, Calif., Sept. 2 /PRNewswi... market leader in document imaging scanners and se... earned the "Editor,s Choice",designation in the B...he,Fujitsu fi-6130, fi-6230, fi-6140, fi-6240, fi-...
Other Biology News:Cardiac cell transplant studies show promise in cardiac tissue repair 2What a sleep study can reveal about fibromyalgia 2What a sleep study can reveal about fibromyalgia 3Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 2Fujitsu Scanners Selected as 'Editor's Choice' in Better Buys for Business 2008 Scan-to-File Guide 3
Rabbit Anti-Human Sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 7 (SIRT7) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
...te sealer with an integrated in-line plate stacker...configurations and sealing capabilities. ,Featur...240-plate storage capacity , Integrated with Hudso...les all SBS microplates and tube racks , Variety o...
...of mouse embryonic stem cells to dopaminergic neur...here they are mainly located in the substantia nig...l field. These dopaminergic (DA) neurons give rise....projections to the caudate nucleus, putamen nucle...
...mer screening and binding optimization and built o...n-chip synthesis platform. Thousands of customer s...LC Sciences can provide assistance with custom seq...art of our comprehensive DNA/RNA Aptamer Microarra...
Biology Products: